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Abstract 
 
Background & aims: Esophageal cancer (EC) is a significant cause of cancer-related 
mortality worldwide. Statins have anti-carcinogenic effects in EC cell lines. The aim of this 
study was to determine whether statin use following diagnosis of EC, including the 
histological subtypes, is associated with reduced EC-specific and all-cause mortality.  
Methods: A cohort of 4445 men and women in the United Kingdom diagnosed with EC 
between January 2000 and November 2009 and followed-up until November 2011 were 
identified using the General Practice Research Database. Cox proportional hazard 
regression analysis with time-dependent exposures estimated the association between 
post-diagnostic statin use and EC-specific and all-cause mortality.  
Results: The median survival of the whole cohort was 9.2 months (IQR 3.7-23.2). The 
median survival in post-diagnostic statin users was 14.9 months (IQR 7.1-52.3) and in 
non-users was 8.1 months (IQR 3.3-20).  Post-diagnostic statin use was associated with 
a decreased risk of EC-specific mortality (adjusted Hazard Ratio [HR] 0.62, 95% CI 0.44-
0.86) and all-cause mortality (HR 0.67, 95% CI 0.58-0.77) for the full cohort. In patients 
with esophageal adenocarcinoma (EAC), post-diagnostic use of statins was associated 
with decreased risk of EC-specific mortality (HR 0.61, 95% CI 0.38-0.96) and all-cause 
mortality (HR 0.63, 95% 0.43-0.92). This effect was not observed in patients with 
esophageal squamous cell carcinoma (ESCC). There was no evidence of effect 
modification on associations by pre-diagnostic statin use. 
Conclusions: In a large population-based cohort, post-diagnostic statin use in patients 
with EC was associated with reduced EC-specific and all-cause mortality, specifically in 
those with EAC but not ESCC. 
Keywords: HMG-CoA; esophagus 
  
4 
 
Introduction 
 
Esophageal cancer (EC) is the 5th and 8th most common cause of cancer-related death 
in men and women respectively worldwide1. Of the two main histological subtypes, 
esophageal squamous cell carcinoma (ESCC) is globally predominant, while esophageal 
adenocarcinoma (EAC), the incidence of which has rapidly risen since the 1970s, is the 
most common form in the west1, 2. Most patients with EC present with advanced disease 
and are often only amenable to palliative management. Consequently, the overall 5-year 
survival rate is approximately only 15%3.  
 
Novel clinical interventions to improve prognosis in patients with EC are required. There 
has been a considerable research focus on the potential anti-cancer effects of statins (3-
hydroxy-3-methylglutaryl coenzyme A [HMG-CoA] reductase inhibitors), which are 
commonly prescribed for the primary and secondary prevention of cardiovascular 
disease4. A body of basic research has demonstrated that statins promote apoptosis and 
limit proliferation in EAC and ESCC cell lines5-8. Epidemiological investigations have 
demonstrated that use of statins post-diagnosis is associated with reduced risk of cancer-
specific mortality in a number of malignancies, including prostate, breast and colorectal 
carcinoma9-11. Furthermore, at a population level their use is inversely associated with 
development of the histological subtypes of EC12. A population-based cohort study in 
Denmark demonstrated that statin use prior to diagnosis of EC was associated with a 
19% decrease in cancer-specific mortality13.  Whether statin use following diagnosis of 
EC, a more relevant time period for clinical intervention, improves survival is unknown. 
Furthermore, whether or not statins exert differential effects on survival for the two main 
histological subtypes, EAC and ESCC, is unknown. Therefore, the primary aim of this 
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epidemiological study was to determine whether statin use following diagnosis of EC, 
including the histological subtypes, is associated with reduced EC-specific and all-cause 
mortality. Secondary aims were to determine whether pre-diagnostic statin use is an 
effect modifier on the association between post-diagnostic statin use and survival; 
determine whether a dose-response relationship exists; and determine whether 
differential effects exist according statin type. 
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Methods 
 
Data sources 
This study was conducted using three databases: the United Kingdom (UK) General 
Practice Research Database (GPRD), the UK National Cancer Registry (NCR) and the 
Office of National Statistics (ONS) database. The GPRD is the world’s largest electronic 
database of prospective demographic, lifestyle and medical data in a primary care 
setting14. At the time of data extraction, 4 million patients were registered at 488 general 
practices, covering 6% of the UK population. The age and sex distributions of participants 
in the GPRD are comparable with the National Population Census, and the distribution of 
participating practices is representative of the UK population15. General Practitioners 
(GPs) prospectively record incident diagnoses and medical procedures using a modified 
Read/Oxford Medical Information System (OXMIS) classification system. Filled drug 
prescriptions issued by GPs are automatically recorded and coded using the UK 
Prescription Pricing Authority Dictionary. Data recorded on diagnostic codes to identify 
diseases, including EC, and drug prescriptions in the GPRD have been shown to be valid 
in independent studies16-18. Linkage between databases used a deterministic algorithm 
based on the patient National Health Service number, postcode, gender and date of birth. 
The NCR contains information on tumour site (coded using the International Classification 
of Diseases, 10th Revision [ICD-10]), histology, cancer stage and treatment modalities. 
Approximately half of GPRD practices were linked to the NCR at the time of data 
extraction. For patients with data linked to the NCR, ONS data was available to determine 
cause of death. The GPRD group have obtained blanket approval from a multi-centre 
ethics committee for observational research conducted within the database. 
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Study cohort 
Participants with incident esophageal or esophagogastric junction cancers, diagnosed 
between 1st January 2000 to 30st November 2009, and followed-up until 1st November 
2011 were identified from the GPRD. Patients were included with no prior history of 
cancer. All patients were required to be diagnosed at least one year after the contributing 
practice had received its “up-to-standard” date: the time from which the practice was 
considered to generate continuous high quality data fit for research. The histological 
subtype for a subset of patients was determined through linkage to the NCR. ICD codes 
were used to confirm esophageal (C15) and esophago-gastric junctional (C16) cancers, 
and specific morphology codes were used to obtain the histological subtypes: EAC, 
esophagogastic junctional adenocarcinoma (EGJA) and ESCC. Follow-up was from the 
date of diagnosis until death, or until they were transferred out of the GPRD or the date 
of last data entry, whichever came first. 
 
Statin use 
Exposure to the following statins currently in clinical use in the UK were extracted: 
Simvastatin, Atorvastatin, Pravastatin, Rosuvastatin and Fluvastatin.  Post-diagnostic 
statin use was defined as a prescription of any of these statins recorded in the GPRD at 
any time after the date of diagnosis. Post-diagnostic statin use was included as a time-
dependent covariate in the models to avoid immortal-time bias: whereby a span of cohort 
follow-up during which death could not occur (i.e. between diagnosis and the first statin 
prescription) is inappropriately introduced due to the definition of the exposure of 
interest19. Patients were considered unexposed until the first post-diagnosis prescription, 
from which point they were considered continuously exposed until the end of follow-up. 
Deeming patients continuously exposed sought to minimize reverse causation bias, 
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whereby ultimately discontinuation could reflect poor prognosis and therefore death may 
otherwise be more likely inappropriately classified during an “unexposed” period20. 
Exposure to the individual statins listed above was also considered in survival analyses. 
To investigate the possibility of healthy survivor bias in the statin users post-diagnosis, 
the intervals between diagnosis and statin initiation for all statin users post-diagnosis were 
presented using a Kaplan-Meier plot (Supplementary figure 1).  
 
Pre-diagnosis statin use was also an exposure of interest. It was defined as a prescription 
of any of the statins recorded above in the GPRD for a minimum of two months between 
6 and 18 months prior to diagnosis. This definition sought to minimize reverse causation 
bias, whereby symptomatic EC (and hence likely more advanced disease) could influence 
prescribing practice or medication use. Pre-diagnosis statin use was determined for the 
following three reasons: it was entered as a covariate in models of post-diagnostic statin 
use to determine whether it modifies the effect of post-diagnosis statin use on survival; in 
sensitivity analyses the association between pre-diagnosis statin use on survival was 
determined to consider an exposure to statin use, alternative to post-diagnosis statin use, 
in which the potential effect of reverse-causation bias would be expected to be minimal; 
and finally it was used to determine categories for dose-response analyses. Statin users 
were categorized as low (equivalent to ≤ 20mg simvastatin) or high (equivalent to > 20mg 
simvastatin) dose users based on the mean daily dose for statin prescriptions collected 
between 6-18 months prior to diagnosis. Cumulative statin dose was determined using 
categories of cumulative defined-daily dose (DDD). The DDD, a standardized measure 
of drug exposure as defined by the World Health Organization, is the assumed average 
maintenance dose per day for a drug used for its main indication in adults21. For example, 
1 DDD is equivalent to a single dose of 30mg Simvastatin or 20mg Atorvastatin. The 
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median cumulative DDD collected between 6-18 months prior to diagnosis in the whole 
cohort was the threshold for cumulative dose categories. Post-diagnostic mean or 
cumulative dose-response analyses were not examined a priori as the dose categories 
would be expected to be a function of survival time. In a post-hoc analysis we conducted 
dose-response analyses using the dose (expressed in DDDs) of the first statin prescribed 
post-diagnosis to determine the dose category. 
 
Covariates 
The following covariates which could plausibly confound associations between post-
diagnostic statin use and survival were extracted from the GPRD: age at diagnosis, 
gender, body mass index (BMI) at the time closest to and preceding diagnosis, smoking 
status, cardiovascular diseases (coronary artery, cerebrovascular and peripheral 
vascular disease) and diabetes mellitus, surgery (either esophagectomy, esophago-
gastrectomy or extended gastrectomy) recorded within 6 months of diagnosis and 
medication use (aspirin, angiotensin converting enzyme inhibitors [ACEi] and angiotensin 
2 receptor blockers [ARBs], beta-blockers and non-steroidal anti-inflammatory drugs 
[NSAIDs]). Use of these medications were extracted both post-diagnosis and pre-
diagnosis using the same exposure definitions as for statin use. The following covariates 
were extracted from the NCR: chemotherapy, radiotherapy and surgery (either 
esophagectomy, esophago-gastrectomy or extended gastrectomy) recorded within 6 
months of diagnosis. 
 
Outcome measures 
The outcome measures were EC-specific and all-cause mortality. All-cause mortality was 
determined for all study patients in the GPRD. EC-specific mortality was determined for 
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the subset of participants with data linked to the NCR and ONS datasets where EC was 
listed in part one of the death certificate.  
 
 
Statistical analysis 
Descriptive statistics were used to summarize the characteristics of the cohort, including 
the histological subtypes; and separately for pre and post-diagnosis statin users. The 
characteristics between statin users and non-users were compared using the Chi-
squared test for categorical data, two sample t-test for age and the Mann-Whitney U test 
for survival time. Crude rates of EC-specific and all-cause mortality were calculated which 
reflect time-dependent exposure to statins. To account for the time-varying nature of drug 
exposures, Cox proportional hazard regression with time-dependent exposures, 
estimated the associations between statin use (versus non-use) post-diagnosis on EC-
specific and all-cause mortality for the full cohort and the histological subtypes. 
Concomitant medication use and surgery were included as time-dependent covariates in 
the models. Surgery was not included in multivariable analyses of the full cohort (total 
EC, n= 4445) as it was under-recorded in the GPRD, however it was included with cohorts 
linked to the NCR, where it was more comprehensively recorded. Survival curves 
according to post-diagnosis statin use were constructed using Cox proportional hazard 
regression with time-dependent exposures. For analyses of pre-diagnosis statin use, 
follow-up began from the date of diagnosis, and all included covariates were measured 
prior to this date. Cancer stage was incomplete for 95.9% of the cohort and was therefore 
not included in multivariable analyses. Tests for interaction examined for any effect 
modification of pre-diagnosis statin use on the association between post-diagnostic statin 
use and mortality. A test for linear trend was applied across dose categories.  
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Sensitivity analyses 
We performed a number of sensitivity analyses to determine the robustness of our 
findings. As previously outlined, the association between pre-diagnosis statin use on EC-
specific and all-cause mortality for the full cohort and the histological subtypes was 
examined. To determine whether treatment modality (surgery, chemotherapy and 
radiotherapy) was an important confounder in the relationship between post-diagnostic 
statin use and EC-specific and all-cause mortality, analyses were repeated with and 
without these covariates in the model. To explore the potential impact of reverse 
causation bias on analyses of post-diagnostic statin use and consider latency, the cohort 
was restricted to those surviving at least three months, all drug exposures were lagged 
for at least three months and all new prescriptions in the final three months of life were 
ignored. In a post-hoc analysis, the effect of post-diagnosis statin use on-cause and EC-
specific mortality stratified by pre-diagnosis cardiovascular disease status were 
performed as effect sizes could differ according to their indication (primary versus 
secondary prevention). All analyses were performed with STATA version 11 (StataCorp 
LP, College Station, Texas, USA). 
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Results 
 
Cohort 
In total, 4676 patients identified from the GPRD with esophageal or esophago-gastric 
junctional carcinoma met the inclusion criteria (figure 1). From these, 231 (5%) patients 
were excluded as they had no follow-up from diagnosis. The main cohort (total EC) 
comprised 4445 patients of whom 3655 died during follow-up. In total, 1530 (34.4%) 
patients were linked to the NCR in whom there were 1323 all-cause and 805 EC-specific 
deaths. Of these 1165 had complete information on both histology and site including 602 
with EAC, 221 with EGJA and 342 with ESCC.  
 
Clinical characteristics 
Overall, patients in the whole cohort were more likely to be male, smokers and overweight 
or obese (table 1). Median survival for the whole cohort was 9.2 months (inter-quartile 
range 3.7-23.2). Post diagnosis statin use was observed in 18.7% of patients. Accounting 
for immortal-time, the median survival in post-diagnosis statin users was 14.9 months 
(IQR 7.1-52.3) and in non-users was 8.1 months (IQR 3.3-20).  Most patients with EAC 
and EGJA were male and overweight, whereas the majority of patients with ESCC were 
female and had a normal or low BMI. Data on surgery was more complete for the 
histological subtypes (as additional surgical data was available from the NCR) than the 
whole cohort. Pre and post-diagnosis statin use was more common among patients with 
EAC and EGJA than for those with ESCC.  
 
Pre and post-diagnosis statin users (compared to no pre and no post-diagnosis statin 
users respectively) were more likely to be older, male, overweight, smokers, have 
  
13 
 
associated cardiovascular diseases or diabetes, and use aspirin, ACEi/ARBs or beta-
blockers (all p values < 0.001) (table 2). Post-diagnosis statin users were more likely to 
have undergone surgery compared to those who did not use statins post-diagnosis 
(24.9% vs. 21.2% respectively, p = 0.018); whereas pre-diagnosis statin users were less 
likely to have undergone surgery than those who did not use statins pre-diagnosis (17.5% 
vs. 23% respectively, p < 0.001). 830 patients were prescribed statins post-diagnosis in 
the whole cohort, of whom 163 were new users. Of these 117 (72%) were started without 
a prior history of cardiovascular disease (suggesting their indication for primary 
prevention), and 46 (28%) were started after a record of cardiovascular disease 
(suggesting their indication for secondary prevention). Of all patients who used statins 
following diagnosis, 90% were prescribed within 6 months of diagnosis (supplementary 
figure 1). 
 
Post-diagnosis statin use and survival 
In the full cohort post-diagnosis statin use was associated with decreased EC-specific 
(HR 0.62, 95% CI 0.44-0.86) and all-cause mortality (HR 0.67, 95% CI 0.58-0.77) (table 
3, figure 2 and 3). Post-diagnosis statin use was associated with reduced EC-specific (HR 
0.61, 95% CI 0.38-0.96) and all-cause mortality (HR 0.63, 95% CI 0.43-0.92) in patients 
with EAC only, but not for the other subtypes.  There was no significant interaction of pre-
diagnosis statin use on the effect of post-diagnostic statin use on EC-specific or all-cause 
mortality for whole cohort or the subtypes. Post-diagnosis use of Simvastatin and 
Atorvastatin, but not the other statins, was associated with reduced EC-specific mortality 
(supplementary table 2). Post-diagnosis use of each of the individual statins investigated 
was associated with decreased all-cause mortality. 
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Dose-response associations 
No significant dose-response associations for either mean dose or cumulative dose in the 
6-18 months prior to diagnosis were observed in the cohort for which EC-specific mortality 
data was available (n=1530) (p for trend 0.486 and 0.718 respectively) (table 4). However, 
for all-cause mortality (n = 4445) there were significant dose-response associations for 
mean and cumulative dose categories (p for trend 0.003 and 0.002 respectively). For the 
dose response analyses defined by the first prescribed statin dose post diagnosis, while 
there were significant trends across dose categories, the point estimates did not 
consistently decrease from low to high dose use. 
 
Sensitivity analyses 
Pre-diagnosis statin use was associated with decreased all-cause mortality (HR 0.87, 
95% CI 0.78-0.96) but not EC-specific mortality (HR 0.90, 95% CI 0.71-1.16) for the full 
cohort (supplementary table 1). No significant associations were observed between pre-
diagnosis statin use and EC-specific and all-cause mortality for the histological subtypes. 
Including and excluding treatment modality (surgery, chemotherapy, radiotherapy) as 
individual covariates in models in analyses of post-diagnostic statin use did not materially 
alter the strength or precision of estimates (supplementary table 3). Restricting the cohort 
to those who survived at least 3 months from diagnosis had a variable impact on 
associations between post-diagnostic statin use and survival: associations remained a 
similar magnitude in the full cohort for the assessment of all-cause mortality (main 
analysis: HR 0.67, 95% CI 0.58-0.77; sensitivity analysis: HR 0.70, 95% CI 0.60-0.82), 
however lost significance in the assessment of EC-specific mortality  (main analysis: HR 
0.62, 95% CI 0.44-0.86; sensitivity analysis HR 0.84, 95% CI 0.58-1.20). Lagging drug 
exposures weakened associations with EC-specific and all-cause mortality in the full 
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cohort while they were strengthened for associations in patients with EAC. Ignoring new 
prescriptions in the final three months of follow-up did not materially alter associations for: 
EC-specific mortality for the full cohort (main analysis: HR 0.62, 95% CI 0.44-0.86; 
sensitivity analysis: HR 0.60, 95% CI 0.43-0.84); all-cause mortality for the full cohort 
(main analysis: HR 0.67, 95% CI 0.58-0.77; sensitivity analysis: HR 0.54, 95% CI 0.47-
0.63); EC-specific mortality in patients with EAC (main analysis: HR 0.61, 95% CI 0.38-
0.96; sensitivity analysis: HR 0.53, 95% CI 0.32-0.85); or for all-cause mortality in patients 
with EAC (main analysis: HR 0.63, 95% CI 0.43-0.92; sensitivity analysis: HR 0.49, 95% 
CI 0.33-0.73). For sensitivity analyses which stratified for pre-diagnosis cardiovascular 
disease status, risk of EC-specific mortality with post-diagnosis statin use was HR 0.66, 
95% CI 0.44-1.00 (no cardiovascular disease) and HR 0.35, 95% CI 0.20-0.63 (with 
cardiovascular disease); and for all-cause mortality with post-diagnosis statin use HR 
0.66, 95% CI 0.56-0.79 (no cardiovascular disease) and HR 0.66, 95% CI 0.52-0.83 (with 
cardiovascular disease). 
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Discussion 
 
This large population-based cohort study of patients with incident EC found that post-
diagnosis statin use was associated with a 39% reduction in EC-specific mortality and 
33% reduction in all-cause mortality. In patients with EAC specifically, post-diagnosis 
statin use was associated with a 39% reduction in EC-specific mortality and 37% 
reduction in all-cause mortality. There were no significant improvements in survival 
associated with post-diagnosis statin use for ESCC or EGJA. Pre-diagnosis statin use did 
not significantly modify effects observed for post-diagnosis statin use on mortality. 
Significant dose and cumulative dose-response relationships were observed for pre-
diagnosis statin use and all-cause mortality in the whole cohort. Estimates of the 
association between statin use and mortality for the histological subtypes, EGJA and 
ESCC, including the dose-response analyses with EC-specific mortality as the outcome, 
lacked precision. It therefore may not be possible to exclude a weak or moderate effect 
in these groups. While there were significant trends across dose categories defined by 
the first prescribed statin dose post-diagnosis, the estimated hazard ratios did not 
consistently decrease from low to high dose use suggesting that we should cautiously 
interpret this finding. It should be noted this approach would not take into account 
changes in dose or a cumulative exposure.   
 
Biological mechanisms 
Our findings are consistent with experimental studies which have demonstrated that 
statins promote apoptosis and limit proliferation in EAC cell lines5-8. Inhibition of HMG-
CoA reductase by statins decreases production of downstream intermediates of the 
mevalonate pathway, including farnesyl pyrophosphate, which are required for the 
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prenylation and consequent membrane localisation of guanosine-triphosphate-bound 
proteins, including Ras22. Through limiting Ras farnesylation, statins reduce two protein 
kinases, extracellular signal-related protein kinase and protein kinase B/Akt, both of which 
are responsible for promoting cell survival and growth signal transduction in EAC cell 
lines5. Statins also reduce, in a dose-dependent manner, intracellular adhesion molecule-
16, an adhesion molecule involved in trans-endothelial tumour cell migration and 
metastatic spread23, 24. Whether these mechanisms operate to explain the associations 
observed in this study is not clear. 
 
Comparison with previous work 
As far as we are aware, this is the first observational study to investigate the effect of 
statin use post-diagnosis on survival in patients with EC. However, one large 
observational study of 295, 925 patients diagnosed with cancer of any site within the 
entire Danish population examined the effect of statin use pre-diagnosis on cancer-
specific mortality13. This study used the definition of pre-diagnosis statin exposure 
employed in our study. In a sub-analysis of 4, 398 cases of EC (as a composite 
diagnosis), pre-diagnosis statin use was associated with reduced cancer-specific 
mortality (adjusted HR 0.81, 95% CI 0.69-0.95).  This was similar to the effect size that 
we observed (HR 0.87, 95% CI 0.78-0.96) on all-cause mortality (n = 4445). However, 
while the effect size for pre-diagnosis statin use on EC-specific mortality in our study was 
similar, the estimate lacked precision, likely reflecting limited power to detect associations 
(HR 0.90, 95% CI 0.71-1.15) (n = 1530). Similarly to our study, significant amounts of 
data were missing for cancer stage, radiotherapy and chemotherapy. Use of concomitant 
medications that could plausibly confound associations were not included in multivariable 
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analyses. The effect of dose-response on EC mortality specifically was not reported. This 
study did not determine associations according to the histological subtype. 
 
Strengths and limitations 
This study had several strengths. Read codes used to identify patients with EC in the 
GPRD have been shown to be valid (positive predictive value 0.97, sensitivity 0.92, and 
specificity 0.99)18. Overall five-year survival was 12.5%, consistent with UK data, 
suggesting the disease identified was clinically representative3. Participants with EC 
identified from the GPRD represent a large cohort with a median 9 (IQR 3.7 – 22.7) 
months follow-up post diagnosis to enable meaningful survival analyses. In a subset of 
patients, linkage with the NCR enabled associations between statin use and mortality for 
the histological subtypes of EC; and linkage with the ONS database enabled EC-specific 
mortality to be examined. Prospective prescription records within the GPRD avoid recall 
bias compared to self-reported medication use. Measurement error of drug exposures is 
likely to be minimal given the accuracy of prescription records in the GPRD17. While the 
GPRD does not record purchased over-the-counter medications, exposure 
misclassification for statin use is unlikely as such purchases account for only 0.7% of total 
statin use in the UK25. While the GPRD records prescribed medications, exposure 
misclassification could foreseeably arise where patients did not adhere to treatment: while 
prescriptions are accurately recorded by the GPRD, drug adherence is not directly 
captured. However, exposure misclassification through both sources would be expected 
to attenuate associations and underestimate the associations observed in this study. For 
analyses of post-diagnosis statin use, the time-varying nature of drug exposures were 
accounted for and therefore avoided immortal time bias, which would have otherwise 
likely exaggerated associations. A form of selection bias, healthy survivor bias, could 
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have influenced results for individuals who were prescribed their first statin after a 
substantial interval following diagnosis: this group would by definition have an improved 
prognosis as their risk of death due to the index cancer would be expected to diminish as 
the interval lengthened. However, this potential bias would seem unlikely to have 
influenced results overall as 90% of patients who were prescribed statins post-diagnosis, 
did so within 6 months (supplementary figure 1). 
 
This study has several limitations. There were substantial amounts of missing data for 
treatment modality and cancer stage. Completeness of treatment modality approached 
that expected for surgery and radiotherapy but not chemotherapy for patients linked to 
the cancer registry. For example, for EAC patients the proportion receiving surgery, 
chemotherapy, and radiotherapy, respectively, was 33%, 24% and 15% and national 
audit data indicate the approximate expected proportions to be 35%, 47% and 12%26. 
While treatment modality and stage are important predictors of outcomes, it is not clear 
as to whether they operate as confounders in the association between statin use and 
mortality. As clinical staging and treatment modality are closely related, treatment 
modality could be regarded as a proxy for staging: with surgery expected to be most 
discerning from the three captured modalities. Therefore, sensitivity analyses were 
conducted (outlined above), to explore whether treatment modality, and by extension 
cancer staging, could operate as confounders in the association between statin use and 
mortality. Effect sizes and the precision of the estimates were similar for post-diagnosis 
statin use in analyses which did and did not adjust for surgery, chemotherapy and 
radiotherapy; suggesting that unmeasured confounding by treatment modality or clinical 
stage was not operating.  
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Reverse causation bias could theoretically operate in the association between post-
diagnosis statin use and mortality. New users could represent a group with a more 
favorable prognosis, as determined by their GP, such that for these individuals prevention 
of cardiovascular disease (particularly primary prevention), a long-term outcome, is 
deemed a clinical priority, as opposed to adopting a more palliative approach. Although 
we cannot exclude this, our findings would suggest this mechanism of reverse causation 
bias is not a prominent explanation for the associations observed. First, of all statin users 
post-diagnosis, new statin users who were likely prescribed statins for primary prevention 
accounted for a minority (14%). Second, there was no significant interaction with statin 
use prior to diagnosis for the association between post-diagnosis statin use and EC-
specific and all-cause mortality. Third, restricting the whole cohort to those surviving 
greater than three months from diagnosis did not materially alter associations in the whole 
cohort (associations examined with linked data were likely underpowered to assess this). 
Restricting the cohort to those surviving longer periods would have been underpowered: 
the prognosis from EC overall is poor and the remaining cohort size would be too small 
to permit meaningful analyses. Fourth, one would expect reverse causation bias to 
operate in the same manner as for other medications exposures used in the treatment of 
cardiovascular diseases (assuming they do not cause harm): indeed significant 
associations were not observed (all p values > 0.05). Fifth, pre-diagnosis statin use, a 
measure of statin exposure which would be expected to be free of reverse causation bias, 
was associated with reduced all-cause mortality. Deeming patients continuously exposed 
to statins once a prescription was issued until the end of follow-up prevented another 
guise of reverse causation bias, whereby treatment decisions made at the end-of-life, 
such as withdrawing regular medications, ensured patients were correctly classified as 
exposed. Similarly, sensitivity analyses which ignored all new prescriptions in the final 
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three months’ of follow-up, an exposure which may not plausibly influence outcomes but 
which could reflect a GP’s assessment of prognosis, did not materially alter the strength 
or significance of associations. 
 
The analyses may be susceptible to unmeasured confounding mediated by a healthy-
user effect: statin users could represent a more health conscious group, whereby 
associated behaviors, either on the part of the patient or health-professional, may be 
associated with improved survival. For example, more health-conscious individuals may 
present and be diagnosed with an earlier stage of cancer; and GP have been reported to 
selectively under-prescribe lipid-lowering medications to obese patients or smokers27, 
both of which are associated with increased cancer-related mortality28, 29. However, 
contrary to this, statin users appeared less healthy: they were more likely to be overweight 
or obese, smoke and have diabetes or cardiovascular disease than non-users - factors 
which independently predict mortality. Nevertheless, we attempted to minimize potential 
confounding from a healthy-user effect by including smoking, BMI, cardiovascular 
disease and concomitant medication use in multivariable analyses. Nevertheless, as with 
all observational studies, residual confounding is still possible. 
 
Conclusions 
In summary, post-diagnosis statin use was associated with large and significant 
reductions in EC-specific and all-cause mortality, specifically in those with EAC. There 
was evidence of significant dose and cumulative dose-response relationships with pre-
diagnosis statin use on all-cause mortality in patients with EC. These results require 
replication in other large cohorts and provide further evidence in support of the conduct 
of randomized controlled trials of statins as adjuvant agents in patients with EC. 
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Figure 1. Flow chart of study participants 
Abbreviations: EAC, esophageal adenocarcinoma; EC, esophageal carcinoma; EGJA, 
esophagogastric junctional adenocarcinoma; ESCC, esophageal squamous cell carcinoma 
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Figure 2. Adjusted time-dependent Cox proportional hazard regression survival curves 
with hazard ratios for esophageal cancer-specific mortality stratified according to post-
diagnosis statin use 
 
Abbreviations: ACEi, angiotensin conversing enzyme inhibitor; ARB, angiotensin receptor 
blocker; CI, confidence interval; HR, hazard ratio; NCR, National Cancer Registry; NSAID, non-
steroidal anti-inflammatory drugs  
A – Total esophageal carcinoma cases linked to NCR (n = 1222)  
B – Esophageal adenocarcinoma (n=470) 
C – Esophagogastric junctional adenocarcinoma (n=184)  
D – Esophageal squamous cell carcinoma (n = 267)  
All adjusted for age, gender, body mass index, smoking status, cardiovascular diseases, 
diabetes, surgery, pre-diagnosis statin use, post-diagnosis use of aspirin, beta-blockers, 
ACEi/ARBs and NSAIDs 
Only cases with complete body mass index and smoking data included 
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Figure 3. Adjusted time-dependent Cox proportional hazard regression survival curves 
with hazard ratios for all-cause mortality stratified according to post-diagnosis statin use 
 
 
Abbreviations: ACEi, angiotensin conversing enzyme inhibitor; ARB, angiotensin receptor 
blocker; CI, confidence interval; HR, hazard ratio; NSAID, non-steroidal anti-inflammatory drugs  
A – Total esophageal carcinoma cases (n = 3595)  
B – Esophageal adenocarcinoma (n=470) 
C – Esophagogastric junctional adenocarcinoma (n=184)  
D – Esophageal squamous cell carcinoma (n = 267)  
A adjusted for age, gender, body mass index, smoking status, cardiovascular diseases, 
diabetes, pre-diagnosis statin use, post-diagnosis use of aspirin, beta-blockers, ACEi/ARBs and 
NSAIDs 
B, C, D adjusted for above including surgery 
Only cases with complete body mass index and smoking data included 
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Table 1. Baseline demographic and clinical characteristics of the cohort and stratified by 
histological subtype and site 
 
 
Abbreviations: ACEi, angiotensin conversing inhibitor; ARB, angiotensin receptor blocker; EC, 
esophageal cancer; EAC, esophageal adenocarcinoma; EGJA, esophagogastric junctional 
adenocarcinoma; ESCC, esophageal squamous cell carcinoma; NSAID, non-steroidal anti-inflammatory 
drugs;  
1Percentages presented for unknown categories reflect overall proportion of missing data for the relevant 
covariate; while percentages presented for known categories refer to complete data only 
  
 
 
 
 
 
Total EC EAC EGJA ESCC
Characteristics (n=4445) (n=602) (n=221) (n=342)
Age (years), mean (SD) 70.8 (11.5) 70.7 (11.3) 68.3 (11.6) 71.8 (12.1)
Male gender, n (%) 2913 (65.5) 468 (77.7) 171 (77.4) 136 (39.8)
Smoking status, n (%)
Ever 2701 (64.3) 348 (62.0) 127 (60.2) 187 (59.2)
Unknow n1 244 (5.5) 41 (6.8) 10 (4.5) 26 (7.6)
Body mass index (kg/m2), n (%)
< 25 1460 (40.2) 168 (35.0) 58 (31.4) 160 (59.0)
≥ 25 < 30 1435 (39.5) 215 (44.8) 76 (41.1) 80 (29.5)
≥ 30 737 (20.3) 97 (20.2) 51 (27.6) 31 (11.4)
Unknow n1 813 (18.3) 122 (20.3) 36 (16.3) 71 (20.8)
Comorbidities, n (%)
Diabetes mellitus 347 (7.8) 52 (8.6) 17 (7.7) 18 (5.3)
Cardiovascular diseases 771 (17.3) 99 (16.4) 28 (12.7) 57 (16.7)
Esophageal cancer treatment, n (%)
Surgery 973 (21.9) 196 (32.6) 98 (44.3) 92 (26.9)
Chemotherapy 325 (7.3) 146 (24.3) 60 (27.1) 68 (19.9)
Radiotherapy 231 (5.2) 88 (14.6) 9 (4.1) 78 (22.8)
Median survival, months (IQR) 9.2 (3.7-23.2) 9.6 (4.0-23.3) 10.6 (4.2-24.8) 8.6 (4.0-18.7)
Prior medication use
Statin prescription, n (%) 908 (20.4) 101 (16.8) 30 (13.6) 39 (11.4)
Aspirin prescription, n (%) 998 (22.5) 130 (21.6) 44 (19.9) 74 (21.6)
Beta-blocker prescription, n (%) 685 (15.4) 96 (15.9) 36 (16.3) 51 (14.9)
ACEi or ARB prescription, n (%) 947 (21.3) 117 (19.4) 31 (14.0) 58 (17.0)
NSAID prescription, n (%) 391 (8.8) 51 (8.5) 16 (7.2) 29 (8.5)
Post diagnosis medication use
Statin prescription, n (%) 830 (18.7) 104 (17.3) 35 (15.8) 31 (9.1)
Aspirin prescription, n (%) 839 (18.9) 116 (19.3) 39 (17.6) 48 (14.0)
Beta-blocker prescription, n (%) 709 (16.0) 99 (16.4) 32 (14.5) 43 (12.6)
ACEi or ARB prescription, n (%) 889 (20.0) 109 (18.1) 38 (17.2) 33 (9.6)
NSAID prescription, n (%) 793 (17.8) 128 (21.3) 41 (18.6) 65 (19.0)
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Table 2. Baseline demographic and clinical characteristics of the whole cohort stratified 
by statin use 
 
Abbreviations: ACEi, angiotensin conversing inhibitor; ARB, angiotensin receptor blocker; EC, 
esophageal cancer; EAC, esophageal adenocarcinoma; EGJA, esophagogastric junctional 
adenocarcinoma; ESCC, esophageal squamous cell carcinoma; NSAID, non-steroidal anti-inflammatory 
drugs;  
1Percentages presented for unknown categories reflect overall proportion of missing data for the relevant 
covariate; while percentages presented for known categories refer to complete data only 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No pre-diagnostic statin use Pre-diagnostic statin use p-value No Post-diagnostic statin use Post-diagnostic statin use p-value
Characteristics (n=3537) (n=908) (n=3615) (n=830)
Age (years), mean (SD) 70.4 (12.0) 72.3 (9.3) <0.001 70.7 (11.9) 71.3 (9.2) 0.137
Male gender, n (%) 2249 (63.6) 664 (73.1) <0.001 2291 (63.4) 622 (74.9) <0.001
Smoking status, n (%)
Ever 2037 (61.6) 664 (74.4) <0.001 2102 (62) 599 (73.7) <0.001
Unknow n1 229 (6.5) 15 (1.7) 227 (6.3) 17 (2.0)
Body mass index (kg/m2), n (%)
< 25 1202 (43.1) 258 (30.7) 1246 (43.3) 214 (28.4)
≥ 25 < 30 1085 (38.9) 350 (41.7) 1109 (38.5) 326 (43.2)
≥ 30 505 (18.1) 232 (27.6) 523 (18.2) 214 (28.4)
Unknow n1 745 (21.1) 68 (7.5) 737 (20.4) 76 (9.2)
Comorbidities, n (%)
Diabetes Mellitus 180 (5.1) 167 (18.4) <0.001 236 (6.5) 111 (13.4) <0.001
Cardiovascular diseases 419 (11.8) 352 (38.8) <0.001 491 (13.6) 280 (33.7) <0.001
Esophageal cancer treatment, n (%)
Surgery 814 (23.0) 159 (17.5) <0.001 766 (21.2) 207 (24.9) 0.018
Chemotherapy 282 (8.0) 43 (4.7) 0.323 280 (21.4) 45 (20.5) 0.786
Radiotherapy 202 (5.7) 29 (3.2) 0.265 203 (15.5) 28 (12.8) 0.302
Median survival, months (IQR) 9.2 (3.7-23.3) 9.5 (4.0-23.1) 0.913 8.1 (3.3-20.0) 14.9 (7.1-52.3) <0.001
Prior medication use
Statin prescription, n (%) 0 (0) 908 (100) N/A 262 (7.2) 646 (77.8) <0.001
Aspirin prescription, n (%) 470 (13.3) 528 (58.1) <0.001 572 (15.8) 426 (51.3) <0.001
Beta-blocker prescription, n (%) 371 (10.5) 314 (34.6) <0.001 417(11.5) 268 (32.3) <0.001
ACEi or ARB prescription, n (%) 483 (13.7) 464 (51.1) <0.001 567 (15.7) 380 (45.8) <0.001
NSAID prescription, n (%) 296 (8.4) 95 (10.5) 0.047 306 (8.5) 85 (10.2) 0.103
Post diagnosis medication use
Statin prescription, n (%) 184 (5.2) 646 (71.1) <0.001 0 (0) 831 (100) NA
Aspirin prescription, n (%) 456 (12.9) 383 (42.2) <0.001 390 (10.8) 449 (54.1) <0.001
Beta-blocker prescription, n (%) 419 (11.8) 290 (31.9) <0.001 385 (10.7) 324 (39.0) <0.001
ACEi or ARB prescription, n (%) 493 (13.9) 396 (43.6) <0.001 437 (12.1) 452 (54.5) <0.001
NSAID prescription, n (%) 635 (18.0) 158 (17.4) 0.698 598 (16.5) 195 (23.5) <0.001
<0.001 <0.001
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Table 3. Esophageal cancer-specific and all-cause mortality according to post-
diagnostic use of statins 
 
Abbreviations: ARB, angiotensin receptor blocker; ACEi, angiotensin conversing enzyme inhibitor; EC, 
esophageal cancer; EAC, esophageal adenocarcinoma; EGJA, esophagogastric junctional 
adenocarcinoma; ESCC, esophageal squamous cell carcinoma; NSAID, non-steroidal anti-inflammatory 
drugs 
1Adjusted for age, gender, body mass index, smoking status, cardiovascular diseases, diabetes, surgery, 
pre-diagnosis statin use, post-diagnosis use of aspirin, beta-blockers, NSAIDs, and ACEi/ARBs 
2Adjusted for 1 except surgery 
3p for interaction between pre and post-diagnosis statin use on survival 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mortality rate (95% CI) Unadjusted HR Adjusted HR
Cohort Statin exposure Number of patients, n (%) Person-Years (per 100 person-years) (95% CI) (95% CI) p for interaction
3
EC-specific mortality
Total EC No post-diagnosis statin use 1311 (85.7) 1848.3 38.9 (36.2-41.9) 1.00 (reference) 1.00 (reference)
(n=1530) Post-diagnosis statin use 219 (14.3) 426.8 20.1 (16.3-24.9) 0.71 (0.57-0.89) 0.62 (0.44-0.86)
1
0.817
EAC No post-diagnosis statin use 498 (82.7) 728.6 41.5 (37.0-46.4) 1.00 (reference) 1.00 (reference)
(n = 602) Post-diagnosis statin use 104 (17.3) 237.4 19.8 (14.9-26.4) 0.70 (0.51-0.96) 0.61 (0.38-0.96)
1
0.374
EGJA No post-diagnosis statin use 186 (84.2) 303.1 42.3 (36.6-48.8) 1.00 (reference) 1.00 (reference)
(n = 221) Post-diagnosis statin use 35 (15.8) 66.9 34.6 (21.2-56.5) 0.63 (0.33-1.21) 0.58 (0.20-1.69)
1
0.062
ESCC No post-diagnosis statin use 310 (90.6) 440.0 30.7 (25.0-37.6) 1.00 (reference) 1.00 (reference)
(n = 342) Post-diagnosis statin use 31 (9.1) 46.2 15 (8.0-27.8) 1.08 (0.65-1.81) 0.65 (0.29-1.46)
1
0.756
All-cause mortality
Total EC No post-diagnosis statin use 3615 (81.3) 4905.9 62.2 (60.0-64.5) 1.00 (reference) 1.00 (reference)
(n=4445) Post-diagnosis statin use 830 (18.7) 1379.5 43.7 (40.4-47.3) 0.82 (0.75-0.89) 0.67 (0.58-0.77)
2
0.599
EAC No post-diagnosis statin use 498 (82.7) 728.6 60.7 (55.3-66.6) 1.00 (reference) 1.00 (reference)
(n = 602) Post-diagnosis statin use 104 (17.3) 237.4 32.0 (25.6-40.1) 0.75 (0.59-0.96) 0.63 (0.43-0.92)
1
0.290
EGJA No post-diagnosis statin use 186 (84.2) 303.1 61.8 (54.9-69.6) 1.00 (reference) 1.00 (reference)
(n = 221) Post-diagnosis statin use 35 (15.8) 66.9 54.1 (36.5-80.0) 0.80 (0.51-1.24) 0.82 (0.38-1.73)
1
0.418
ESCC No post-diagnosis statin use 311 (90.9) 440.0 54.8 (47.0-63.8) 1.00 (reference) 1.00 (reference)
(n = 342) Post-diagnosis statin use 31 (9.1) 46.2 34.4 (22.9-51.8) 1.12 (0.74-1.68) 0.78 (0.41-1.50)
1
0.751
  
30 
 
Table 4. Dose-response associations between statins use and risk of esophageal 
cancer-specific and all-cause mortality 
 
Abbreviations: ACEi, Angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; DDD, 
defined daily dose; EC, esophageal cancer;   
1Adjusted for age, gender, body mass index, smoking status, cardiovascular diseases, diabetes, surgery, 
aspirin, beta-blockers, ACEi/ARB use and NSAIDs 
2Adjusted for 1 except surgery 
3Dose categories determined using the first statin dose prescribed post-diagnosis 
4Low dose equivalent to ≤ 20mg Simvastatin; high dose equivalent to > 20mg Simvastatin 
5Measured between 6-18 months prior to diagnosis of EC 
6Cut off of 224 DDDs selected as the median value in whole cohort 
 
 
 
 
 
 
 
 
 
 
Mortality rate (95% CI) Unadjusted Adjusted
Statin exposure Number of patients, n (%) Person-Years (per 100 person-years) HR (95% CI) HR (95% CI)
EC-specific mortality
Post-diagnosis statin use3
No statin use 1311 (85.69) 1848.3 38.9 (36.2-41.9) 1.00 (reference) 1.00 (reference)
Low  dose statin use4 118 (7.71) 245.1 18.8 (14.1-25.1) 0.70 (0.52-0.95) 0.56 (0.38-0.83)
1
High dose statin use4 101 (6.6) 181.7 22 (16.1-30.0) 0.73 (0.53-1.00) 0.69 (0.46-1.03)
1
P for trend 0.007 0.029
Pre-diagnosis statin use5
No statin use 1301 (85.0) 1980.6 34.8 (32.3-37.5) 1.00 (reference) 1.00 (reference)
Low  dose statin use4 149 (9.7) 232.8 42.4 (33.9-53.1) 1.08 (0.85-1.36) 0.90 (0.68-1.19)
1
High dose statin use4 80 (5.2) 61.7 34.5 (25.2-47.2) 0.89 (0.65-1.23) 0.92 (0.64-1.33)
1
P for trend 0.770 0.486
≥ 1 < 224 DDD6 146 (9.5) 191.2 36.6 (29.0-46.3) 0.97 (0.76-1.24) 0.89 (0.67-1.20)
1
≥ 224 DDD6 83 (5.4) 103.2 44.6 (33.4-59.5) 1.07 (0.79-1.44) 0.99 (0.70-1.39)
1
P for trend 0.820 0.718
All-cause mortality
Post-diagnosis statin use3
No statin use 3615 (81.3) 4905.9 62.2 (60.0-64.5) 1.00 (reference) 1.00 (reference)
Low  dose statin use4 379 (8.5) 691.4 39.5 (35.1-44.5) 0.80 (0.70-0.90) 0.64 (0.54-0.75)
2
High dose statin use4 451 (10.2) 688 48.0 (43.1-53.4) 0.83 (0.74-0.93) 0.70 (0.60-0.82)
2
P for trend <0.001 <0.001
Pre-diagnosis statin use5
No statin use 3537 (79.6) 5128.2 56.8 (54.8-58.9) 1.00 (reference) 1.00 (reference)
Low  dose statin use4 463 (10.4) 570.5 66.6 (60.2-73.7) 1.06 (0.95-1.18) 0.90 (0.80-1.02)
2
High dose statin use4 445 (10.0) 586.6 61.7 (55.7-68.4) 0.95 (0.86-1.07) 0.83 (0.73-0.94)
2
P for trend 0.706 0.003
≥ 1 < 224 DDD6 463 (10.4) 581.2 65.6 (59.3-72.5) 1.04 (0.94-1.16) 0.91 (0.80-1.02)
2
≥ 224 DDD6 445 (10.0) 575.9 62.7 (56.5-69.5) 0.97 (0.87-1.08) 0.82 (0.72-0.93)
2
P for trend 0.789 0.002
  
31 
 
Supplementary table 1.  Esophageal cancer-specific mortality according to pre-
diagnostic use of statins 
 
Abbreviations: ARB, angiotensin receptor blocker; ACEi, angiotensin conversing enzyme inhibitor; EC, 
esophageal cancer; EAC, esophageal adenocarcinoma; EGJA, esophagogastric junctional 
adenocarcinoma; ESCC, esophageal squamous cell carcinoma; NSAID, non-steroidal anti-inflammatory 
drugs 
Adjusted for age, gender, body mass index, smoking status, cardiovascular diseases, diabetes, aspirin, 
beta-blockers, ACEi/ARB use and NSAIDs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mortality rate (95% CI) Unadjusted HR Adjusted HR
Cohort Statin exposure Number of patients, n (%) Person-Years (per 100 person-years) (95% CI) (95% CI)
EC-specific mortality
Total EC No pre-diagnosis statin use 1301 (85.0) 1980.6 34.8 (32.3-37.5) 1.00 (reference) 1.00 (reference)
(n=1530) Pre-diagnosis statin use 229 (15.0) 294.5 39.4 (32.8-47.3) 1.01 (0.83-1.22) 0.91 (0.71-1.16)
EAC No pre-diagnosis statin use 501 (83.2) 817.6 35.5 (31.6-39.8) 1.00 (reference) 1.00 (reference)
(n = 602) Pre-diagnosis statin use 101 (16.8) 148.3 39.8 (30.8-51.3) 1.07 (0.81-1.41) 0.81 (0.55-1.20)
EGJA No pre-diagnosis statin use 191 (86.4) 326.7 27.2 (22.1-33.5) 1.00 (reference) 1.00 (reference)
(n = 221) Pre-diagnosis statin use 30 (13.6) 43.3 32.3 (19.2-54.6) 0.96 (0.55-1.69) 0.82 (0.40-1.69)
ESCC No pre-diagnosis statin use 303 (88.6) 444.2 39.8 (34.4-46.2) 1.00 (reference) 1.00 (reference)
(n = 342) Pre-diagnosis statin use 39 (11.4) 42.0 59.6 (40.3-88.2) 1.21 (0.79-1.84) 1.08 (0.65-1.79)
All-cause mortality
Total EC No pre-diagnosis statin use 3543 (79.6) 5128.2 56.8 (54.8-58.9) 1.00 (reference) 1.00 (reference)
(n=4445) Pre-diagnosis statin use 908 (20.5) 1157.1 64.1 (59.7-68.9) 1.00 (0.93-1.09) 0.86 (0.78-0.95)
EAC No pre-diagnosis statin use 501 (83.2) 817.6 52.6 (47.8-57.8) 1.00 (reference) 1.00 (reference)
(n = 602) Pre-diagnosis statin use 101 (16.8) 148.3 59.3 (48.1-73.1) 1.08 (0.86-1.35) 0.77 (0.56-1.06)
EGJA No pre-diagnosis statin use 191 (86.4) 326.7 50.2 (43.1-58.5) 1.00 (reference) 1.00 (reference)
(n = 221) Pre-diagnosis statin use 30 (13.6) 43.3 57.8 (39.0-85.5) 0.96 (0.63-1.46) 0.72 (0.42-1.24)
ESCC No pre-diagnosis statin use 303 (88.6) 444.2 59.0 (52.3-66.6) 1.00 (reference) 1.00 (reference)
(n = 342) Pre-diagnosis statin use 39 (11.4) 42.0 83.4 (59.9-116.2) 1.18 (0.83-1.68) 0.95 (0.62-1.46)
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Supplementary table 2. Mortality according to first statin type used post-diagnosis of 
esophageal carcinoma 
 
Abbreviations: ARB, angiotensin receptor blocker; ACEi, angiotensin conversing enzyme inhibitor; EC, 
esophageal cancer; NSAID, non-steroidal anti-inflammatory drugs 
1Adjusted for age, gender, body mass index, smoking status, cardiovascular diseases, surgery, diabetes, 
aspirin, beta-blockers, ACEi/ARB use and NSAIDs 
2Adjusted for age, gender, body mass index, smoking status, cardiovascular diseases, diabetes, aspirin, 
beta-blockers, ACEi/ARB use and NSAIDs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mortality rate (95% CI) Unadjusted HR Adjusted HR
Statin type Number of patients, n (%) Person-Years (per 100 person-years) (95% CI) (95% CI)
EC-specif ic mortality
No statin 1311 (85.69) 1703.91 42.2 (39.2-45.4) 1.00 (reference) 1.00 (reference)
Simvastatin 128 (8.37) 381.4 11.8 (8.8-15.8) 0.67 (0.50-0.91) 0.61 (0.41-0.89)
1
pravastatin 20 (1.31) 29.8 33.6 (18.1-62.5) 1.00 (0.54-1.87) 1.09 (0.56-2.12)
1
Atorvastatin 63 (4.12) 137.1 21.9 (15.3-31.3) 0.81 (0.56-1.17) 0.56 (0.35-0.90)
1
rosuvastatin 3 (0.2) 8.7 0 NA NA
fluvastatin 5 (0.33) 14.3 7 (1-49.8) 0.23 (0.03-1.63) 0.24 (0.03-1.76)
1
All-cause mortality
No statin 3615 (81.33) 4592.4 66.5 (64.1-68.9) 1.00 (reference) 1.00 (reference)
Simvastatin 516 (11.61) 1066.3 34.4 (31.1-38.1) 0.83 (0.75-0.93) 0.68 (0.58-0.79)
2
pravastatin 57 (1.28) 132.6 30.9 (22.8-42) 0.69 (0.51-0.94) 0.58 (0.41-0.82)
2
Atorvastatin 214 (4.81) 397.6 42.3 (36.3-49.2) 0.87 (0.74-1.02) 0.70 (0.58-0.85)
2
rosuvastatin 32 (0.72) 56.4 39 (25.7-59.2) 0.68 (0.45-1.04) 0.63 (0.40-0.99)
2
f luvastatin 11 (0.25) 40.0 12.5 (5.2-30) 0.36 (0.15-0.88) 0.33 (0.14-0.80)
2
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Supplementary table 3. Sensitivity analyses for post-diagnostic statin use and 
esophageal cancer-specific and all-cause mortality 
 
Abbreviations: ARB, angiotensin receptor blocker; ACEi, angiotensin conversing enzyme inhibitor; EC, 
esophageal cancer; EAC, esophageal adenocarcinoma; EGJA, esophagogastric junctional 
adenocarcinoma; ESCC, esophageal squamous cell carcinoma; NA, not applicable; NSAID, non-steroidal 
anti-inflammatory drugs 
1Adjusted for age, gender, body mass index, smoking status, cardiovascular diseases, diabetes, surgery, 
pre-diagnosis statin use, aspirin, beta-blockers, ACEi/ARB and NSAID use 
2Adjusted for age, gender, body mass index, smoking status, cardiovascular diseases, diabetes, pre-
diagnosis statin use, aspirin, beta-blockers, ACEi/ARB and NSAID use 
3Adjusted for age, gender, body mass index, smoking status, cardiovascular diseases, diabetes, surgery, 
chemotherapy, radiotherapy, pre-diagnosis statin use, aspirin, beta-blockers, ACEi/ARB and NSAID use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary table 3. Sensitivity analyses for post-diagnostic statin use and esophageal cancer-specif ic and all-cause mortality
Mortality rate (95% CI) Mortality rate (95% CI) Unadjusted HR Adjusted HR
Sesnitivity analyses (post-diagnostic statin use vs. non-use) Number of patients, n (%) (per 100 person-years) Number of patients, n (%) (per 100 person-years) (95% CI) (95% CI)
Total EC
 Esophageal cancer-specific mortality
Adjusted for surgery (main analysis) 219 (14.3) 15.1 (12.2-18.6) 1311 (85.7) 42.2 (39.2-45.4) 0.71 (0.57-0.89) 0.62 (0.44-0.86)
1
Adjusted for surgery, chemotherapy and radiotherapy 219 (14.3) 15.1 (12.2-18.6) 1311 (85.7) 42.2 (39.2-45.4) 0.71 (0.57-0.89) 0.61 (0.44-0.85)
3
Not adjusted for surgery 219 (14.3) 15.1 (12.2-18.6) 1311 (85.7) 42.2 (39.2-45.4) 0.71 (0.57-0.89) 0.65 (0.47-0.90)
2
All patients surviving longer than three months from diagnosis 201 (16.7) 19.1 (15.3-23.7) 1001 (83.3) 30 (27.6-32.6) 0.71 (0.57-0.89) 0.84 (0.58-1.20)
1
Exposure to precriptions lagged by three months 191 (12.5) 20.2 (16.2-25.3) 1339 (87.5) 38.4 (35.7-41.3) 0.84 (0.66-1.07) 0.66 (0.41-1.07)
1
All prescriptions in the f inal three months of follow -up ignored 191 (12.5) 13.5 (10.8-16.9) 1339 (87.5) 42.6 (39.6-45.8) 0.64 (0.50-0.81) 0.60 (0.43-0.84)
1
All-cause mortality
Adjusted for surgery 830 (18.7) 43.7 (40.4-47.3) 3615 (81.3) 62.2 (60-64.5) 0.82 (0.75-0.89) 0.66 (0.58-0.76)
1
Adjusted for surgery, chemotherapy and radiotherapy 830 (18.7) 43.7 (40.4-47.3) 3615 (81.3) 62.2 (60-64.5) 0.82 (0.75-0.89) 0.66 (0.58-0.76)
3
Not adjusted for surgery (main analysis) 830 (18.7) 43.7 (40.4-47.3) 3615 (81.3) 62.2 (60-64.5) 0.82 (0.75-0.89) 0.67 (0.58-0.77)
2
All patients surviving longer than three months from diagnosis 764 (21.8) 32 (29.4-34.8) 2749 (78.3) 49.4 (47.4-51.5) 0.88 (0.80-0.96) 0.70 (0.60-0.82)
2
Exposure to precriptions lagged by three months 723 (16.3) 42.4 (38.9-46.3) 3722 (83.7) 61.8 (59.7-64.0) 0.92 (0.83-1.01) 0.85 (0.74-0.98)
2
All prescriptions in the f inal three months of follow -up ignored 723 (16.3) 30.4 (27.9-33.2) 3722 (83.7) 68.1 (65.7-70.5) 0.67 (0.61-0.74) 0.54 (0.47-0.63)
2
EAC
 Esophageal cancer-specific mortality
Adjusted for surgery (main analysis) 104 (17.3) 19.8 (14.9-26.4) 498 (82.7) 41.5 (37-46.4) 0.70 (0.51-0.96) 0.61 (0.38-0.96)
1
Adjusted for surgery, chemotherapy and radiotherapy 104 (17.3) 19.8 (14.9-26.4) 498 (82.7) 41.5 (37-46.4) 0.70 (0.51-0.96) 0.61 (0.38-0.98)
3
Not adjusted for surgery 104 (17.3) 15.5 (11.6-20.6) 498 (82.7) 41.5 (37-46.4) 0.70 (0.51-0.96) 0.60 (0.37-0.98)
2
All patients surviving longer than three months from diagnosis 98 (20.3) 19.8 (14.9-26.4) 385 (79.7) 32.1 (28.2-36.5) 0.78 (0.56-1.08) 0.83 (0.50-1.36)
1
Exposure to precriptions lagged by three months 93 (15.5) 19.7 (14.6-26.7) 509 (84.6) 40.8 (36.5-45.6) 0.81 (0.58-1.13) 0.47 (0.23-0.98)
1
All prescriptions in the f inal three months of follow -up ignored 93 (15.5) 14.1 (10.4-19.0) 509 (84.6) 46 (41.1-51.4) 0.63 (0.45-0.87) 0.53 (0.32-0.85)
1
All-cause mortality
Adjusted for surgery (main analysis) 104 (17.3) 32 (25.6-40.1) 498 (82.7) 60.7 (55.3-66.6) 0.75 (0.59-0.96) 0.63 (0.43-0.92)
1
Adjusted for surgery, chemotherapy and radiotherapy 104 (17.3) 32 (25.6-40.1) 498 (82.7) 60.7 (55.3-66.6) 0.75 (0.59-0.96) 0.65 (0.44-0.94)
3
Not adjusted for surgery 104 (17.3) 32 (25.6-40.1) 498 (82.7) 60.7 (55.3-66.6) 0.75 (0.59-0.96) 0.63 (0.43-0.94)
2
All patients surviving longer than three months from diagnosis 98 (20.3) 23.1 (18.3-29.2) 385 (79.7) 50.7 (45.6-56.5) 0.80 (0.62-1.04) 0.73 (0.48-1.09)
1
Exposure to precriptions lagged by three months 93 (15.5) 30.5 (23.9-38.9) 509 (84.6) 60.2 (54.9-66) 0.82 (0.62-1.07) 0.59 (0.40-0.88)
1
All prescriptions in the f inal three months of follow -up ignored 93 (15.5) 21.8 (17.1-27.8) 509 (84.6) 67.9 (61.9-74.4) 0.63 (0.49-0.82) 0.49 (0.33-0.73)
1
Statin users Non users
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Supplementary figure 1. Kaplan-Meier plot of time to first statin prescription following 
diagnosis of esophageal carcinoma among post-diagnosis statin users 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
